Navigation Links
Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
Date:4/24/2012

ALLEGAN, Mich., April 24, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its third quarter fiscal 2012 on Tuesday, May 8, 2012 at approximately 8:00 a.m. (ET).  The Company will conduct a conference call at 10:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo's Chairman, President and Chief Executive Officer.

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

The conference call will be available live via webcast to interested parties on the Perrigo website http://www.perrigo.com or by phone 877-248-9413, International 973-582-2737, and reference ID# 69598952.  A taped replay of the call will be available beginning at approximately 2:00 p.m. (ET) Tuesday, May 8, 2012, until midnight Friday, May 25, 2012.  To listen to the replay, call 855-859-2056, International 404-537-3406, access code 69598952.  

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com). 

 

 

 


'/>"/>
SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Perrigo Company to Present at the RBC Capital Markets Healthcare Conference
2. Perrigo Announces the Launch of Loratadine-D 12 Store Brand Labels -- the First Store Brand Launch That Compares to Claritin-D® 12
3. Perrigo Company to Present at the Leerink Swann 2012 Global Healthcare Conference
4. Perrigo Company Announces Quarterly Dividend
5. Perrigo Confirms Filing for Generic Version of Astepro® Nasal Spray and Announcement of Patent Infringement Lawsuit by Meda Pharmaceuticals
6. Perrigo Wins Summary Judgment in Generic Mucinex® Case
7. Perrigo Acquires Assets of CanAm Care for $36 Million
8. Perrigo Company to Present at the 30th Annual J.P. Morgan Healthcare Conference
9. Zacks Industry Outlook Highlights: Vertex Pharma, Human Genome Sciences, Biogen Idec and Perrigo
10. Perrigo Announces FDA Final Approval for Desloratadine
11. Perrigo Expands Infant Formula Distribution in China With Brilite Nutritionals (Shanghai) Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Medimetriks Pharmaceuticals, Inc. announced ... Phase III clinical study for Ozenoxacin, a novel ... owns the exclusive U.S. rights to Ozenoxacin 1% ... at 44 centers with an emphasis on U.S. ... 2 months and older with a clinical diagnosis ...
(Date:7/30/2015)... SAN FRANCISCO , July 30, 2015 ... devices market is expected to reach USD 23.01 ... Grand View Research, Inc. Growing base of geriatric population, ... and infections, and rising level of awareness among target ... impact rendering drivers over the forecast period. According to ...
(Date:7/30/2015)... , July 30, 2015  NanoSmart Pharmaceuticals, Inc., ... platforms, has received Orphan Drug Designation from the ... drug product that uses NanoSmart,s proprietary drug delivery ... dactinomycin for the treatment of Ewing,s sarcoma, a ... granted NanoSmart,s Orphan Drug Designation on the basis ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... of Iomai Adjuvant ... Patch -, ... announced that it has begun dosing in a Phase 1/2,study that will ... in combination with an injected,H5N1 influenza vaccine. The Iomai patch, which ...
... Biopure Corporation,(Nasdaq: BPUR ) today announced that it ... use protocol submitted by the company in July. At,the ... for a Phase,2 randomized trial for the treatment of ... alloantibody anemia but,excluding sickle cell anemia. Hemopure has been ...
Cached Medicine Technology:Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine 2Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine 3Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine 4Biopure Reports on Meeting with the FDA 2Biopure Reports on Meeting with the FDA 3
(Date:7/30/2015)... ... July 30, 2015 , ... Glidewell Laboratories, industry-leading provider of ... magazine, its multimedia publication focused on implant dentistry, is now available in print ... 6, Issue 2, as well as past issues of the dental laboratory’s quarterly ...
(Date:7/30/2015)... ... July 30, 2015 , ... Western University of Health Sciences faculty, students ... World Games, the largest sports and humanitarian event in the world this year and ... World Games, held July 25 through August 2, 2015, benefited from the participation of ...
(Date:7/30/2015)... , ... July 30, 2015 , ... On July 23rd ... billion in taxpayer money to fund the state’s large prison system, which has amassed ... the highest rates of incarceration. In light of President Obama’s recent reduction of non ...
(Date:7/30/2015)... ... July 30, 2015 , ... Quintessa Medical Spa is happy to offer patients ... designed specifically for the elimination of excess tissue under the chin, referred to ... state of Wisconsin to offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, Kybella ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Gummy ... including lip lowering, gum contouring and surgery, as well as the patented gum depigmentation ... that has made him popular with many patients from around the world. , “Like ...
Breaking Medicine News(10 mins):Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2
... Researchers at the Food Technology Plant Special Research Centre ... celiac disease// otherwise called as gluten sensitive enteropathy. This ... known to have enhanced nutritive value and increased shelf ... of gluten, forcing sufferers to follow a strictly gluten-free ...
... plenty of good reasons, the term “trans fat” leaves ... Typically, trans fatty acids are bad for health, but// ... have coaxed out significant health benefits by juggling the ... professor of food science, and graduate student Vishal Jain ...
... today urged Australians to spare a thought this week for ... time of year for most people means joyful gatherings with ... and despair,' Dr Yong said. ,'The social circuit, ... can cause depression for those who are socially isolated. ...
... obstinate, as scientists have discovered, as they portray a ... extremely// difficult to annihilate. In fact radiation could even ... from the University of California, Los Angeles, who are ... cells that get radiation resistant and render breast cancer ...
... producing cane sugar with lower glycaemic index (GI) that it ... ranking system for carbohydrates based on their immediate effect on ... risk of diabetes because they trigger rapid increases in blood ... ,The sugar, developed by firm 'Horizon Science of ...
... 'DNA-diets', advertised extensively on the internet, making tall claims of ... ,A study, spearheaded by researchers at the Economic and Social ... University of Exeter, is the first study of its kind ... diets are also called 'nutrigenomic' diets that are customized diet ...
Cached Medicine News:Health News:Gluten Free Bread: Boon for Celiac Disease 2Health News:Healthy Potato Chips: A Trans Fat Oil With Health Benefits 2
... SPRING-GRIP™ single use nonconductive anchoring devices are ... mm and 12 mm sizes for use ... mm, 5 mm-10 mm, 5 mm-11 mm, ... sizes for use with the VERSAPORT™, SURGISPIKE™, ...
... line of Surgical Access ...unlike any trocar ... trocar system is actually four systems in ... flexible and clinically adaptive to all of ... disposability and bladed or dilating tip styles, ...
... FPK01 Thoracic Trocar Pak contains: ... flexible sleeves and (1) 12mm ... ,FPK02 Thoracic Trocar Pak contains: ... flexible sleeves., ,FPK03 Thoracic ...
... of three separate components: an exchange rod, a ... transparent trocar sleeve. The exchange rod is a ... long. The dilating obturator is tapered and threaded ... opening created by the 10/11mm or the 12mm ...
Medicine Products: